Related Experiment Video
Updated: Jun 9, 2025

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Temporal trends in pediatric cancer mortality: rare cancers lag behind more common cancers
Brian R Englum1, Shalini Sahoo1, Theodore W Laetsch2
1University of Maryland School of Medicine, Baltimore, Maryland, USA.
Insights
Survival rates for common pediatric cancers have significantly improved, but rare pediatric cancers still lag behind. Further research is crucial for these rare diseases to improve outcomes for all children with cancer.
Area of Science:
- Pediatric Oncology
- Cancer Epidemiology
- Survival Analysis
Background:
- Survival rates for common pediatric cancers have improved over time.
- Little is known about survival trends for very rare pediatric cancers or how they compare to common ones.
Purpose of the Study:
- To examine temporal trends in survival for pediatric cancers across different frequency groups (common, intermediate, rare).
- To compare mortality improvements between common and rare pediatric cancers using a large population-based registry.
Main Methods:
- Cohort study utilizing the Surveillance, Epidemiology, and End Results (SEER) registry (1975-2016).
- Analysis included 50,222 patients (0-19 years at diagnosis), categorized by cancer frequency and decade of diagnosis.
- Kaplan-Meier curves and adjusted Cox proportional hazards models were used to compare mortality trends.
Main Results:
- Overall 5-year survival increased from 63% to 86% between the 1970s and 2010s.
- Mortality hazard ratios decreased significantly more for common cancers (HR 0.27 in 2010s) compared to rare cancers (HR 0.60 in 2010s).
- Rare cancers were more prevalent in older children and Black children.
Conclusions:
- Pediatric cancer mortality has dramatically decreased since the 1970s, particularly for common cancers.
- Rare pediatric cancers show slower survival improvements, underscoring the need for increased research and focus.
- Targeted research efforts are essential to address the survival gap in rare pediatric cancers.
Abstract:
Temporal trends demonstrate improved survival for many types of common pediatric cancer. Studies have not examined improvement in very rare pediatric cancers or compared these improvements to more common cancers. In this cohort study of the Surveillance, Epidemiology, and End Results (SEER) registry, we examined patients from 1975 to 2016 who were 0-19 years of age at the time of diagnosis. Cancers were grouped by decade of diagnosis and 3 cancer frequency groups: Common, Intermediate, and Rare. Trends in mortality across decades and by cancer frequency were compared using Kaplan-Meier curves and adjusted Cox proportional hazards models. A total of 50,222 patients were available for analysis, with the top 10 cancers grouped as Common (67%), 13 cancers grouped with Intermediate (24%), and 37 cancers as Rare (9%). Rare cancers had higher rates of children who were older and Black. 5-year survival increased from 63% to 86% across all cancers from the 1970s to the 2010s. The hazard ratio (HR) for mortality decreased from the reference point of 1 in the 1970s to 0.27 (95% CI: 0.25-0.30) in the 2010s in Common cancers, while the HR only dropped to 0.60 (0.49-0.73) over that same period for rare cancers. Pediatric oncology patients have experienced dramatic improvement in mortality since the 1970s, with mortality falling by nearly 75% in common cancers. Unfortunately, rare pediatric cancers continue to lag behind more common and therefore better studied cancers, highlighting the need for a renewed focus on research efforts for children with these rare diseases.
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer

